Benjamin Saylor | Authors


Abiraterone Added to ADT and Docetaxel Prolongs PFS in De Novo mCSPC

June 09, 2021

In men with de novo metastatic castration-sensitive prostate cancer treated in the phase 3 PEACE-1 study, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free surviva.

Investigational PSMA-Targeted Treatment Demonstrates Antitumor Activity in mCRPC

June 04, 2021

In patients with metastatic castration-resistant prostate cancer treated in a phase 1/2a study, the HPN424, a tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager was well tolerated and demonstrated antitumor activity.